pulmonary artery stenosis/pulmonary vein stenosis
Conditions
Interventions
dual-antiplatelet therapy group:dual-antiplatelet
antiplatelet combined with rivaroxaban group:antiplatelet combined with rivaroxaban
Sponsors
Gansu Provincial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1.Age =18 years or =75 years; 2.Performed percutaneous pulmonary angioplasty; 3.Subjects without known contraindication to dual antiplatelet therapy for at least 30 months after enrollment and stent implantation; 4.The subject had consented to participate and had authorized the collection and release of his medical information by signing the "Patient Informed Consent Form". The informed consent was valid for the duration of the trial or until the subject withdrew.
Exclusion criteria
Exclusion criteria: 1.Need for dual antiplatelet therapy, other non-aspirin antiplatelet therapy, or oral anticoagulant therapy. 2.Planned surgery necessitating discontinuation of antiplatelet therapy (>14 days) within the 30 months following enrollment. 3.Patients with abnormal coagulation function or previously diagnosed hematological disorders. 4.Concurrent medical condition with a life expectancy of less than 2 years. 5.Participating in other clinical trials. 6.Estimated glomerular filtration rate <15 mL/min. 7.Any known hepatic disease associated with coagulopathy. 8.History of intracranial hemorrhage or subdural hematoma. 9.Routine use of oral non-steroidal anti-inflammatory drugs (NSAID).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival;Incidence of bleeding events;Cardio-cerebrovascular accident;in-stent stenosis; | — |
Secondary
| Measure | Time frame |
|---|---|
| in-stent thrombosis; | — |
Countries
China
Contacts
Public ContactYunshan Cao
Gansu Provincial Hospital
Outcome results
None listed